{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:21:42Z","timestamp":1784647302399,"version":"3.55.0"},"reference-count":81,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2019,6,27]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Plasma exchange is a highly efficient technique to remove circulating autoantibodies and other humoral factors rapidly from the vascular compartment. It was the first effective acute treatment for peripheral disorders such as Guillain-Barr\u00e9 syndrome and myasthenia gravis before intravenous immunoglobulin became available. The recent recognition of rapidly progressive severe antibody-mediated central nervous system disorders, such as neuromyelitis optica spectrum disorders and anti-N-methyl-D-aspartate-receptor encephalitis, has renewed interest in using plasma exchange for their acute treatment also. In this review we explain the principles and technical aspects of plasma exchange, review its current indications, and discuss the implications for its provision in the UK.<\/jats:p>","DOI":"10.1136\/practneurol-2019-002336","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T17:15:38Z","timestamp":1562951738000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Plasma exchange in neurological disease"],"prefix":"10.1136","volume":"20","author":[{"given":"Chinar","family":"Osman","sequence":"first","affiliation":[{"name":"Neurosciences, Wessex Neurological Centre, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jennings","sequence":"additional","affiliation":[{"name":"Neurosciences, Wessex Neurological Centre, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"El-Ghariani","sequence":"additional","affiliation":[{"name":"Therapeutics and Tissue Services, NHS Blood and Transplant, Sheffield Teaching Hospitals NHS Trust and the University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Pinto","sequence":"additional","affiliation":[{"name":"Neurosciences, Wessex Neurological Centre, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"2025090409492862000_20.2.92.1","first-page":"166","article-title":"Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914","volume":"11","author":"Abel","year":"1990","journal-title":"Transfus Sci"},{"key":"2025090409492862000_20.2.92.2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12629"},{"key":"2025090409492862000_20.2.92.3","doi-asserted-by":"crossref","unstructured":"Brettle RP , Gross M , Legg NJ , et al . Treatment of acute polyneuropathy by plasma exchange. The Lancet 1978;312.doi:10.1016\/S0140-6736(78)91837-8","DOI":"10.1016\/S0140-6736(78)91837-8"},{"key":"2025090409492862000_20.2.92.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1096"},{"key":"2025090409492862000_20.2.92.5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220612"},{"key":"2025090409492862000_20.2.92.6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma-exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"key":"2025090409492862000_20.2.92.7","first-page":"265","article-title":"Plasmapheresis in myasthenia gravis","volume":"88","author":"Dau","year":"1982","journal-title":"Prog Clin Biol Res"},{"key":"2025090409492862000_20.2.92.8","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1981.00510080040003"},{"key":"2025090409492862000_20.2.92.9","unstructured":"Imbach P , Barandun S , Baumgartner C , et al . High-Dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981."},{"key":"2025090409492862000_20.2.92.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"2025090409492862000_20.2.92.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"2025090409492862000_20.2.92.12","doi-asserted-by":"crossref","unstructured":"R\u00f8nager J , Ravnborg M , Hermansen I , et al . Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001.","DOI":"10.1046\/j.1525-1594.2001.06717.x"},{"key":"2025090409492862000_20.2.92.13","unstructured":"Plasma Exchange \/ Sandoglobulin Guillain-Barre Syndrome Trial Group . Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. plasma Exchange\/Sandoglobulin Guillain-Barre syndrome trial group. Lancet 1997."},{"key":"2025090409492862000_20.2.92.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"2025090409492862000_20.2.92.15","doi-asserted-by":"crossref","unstructured":"Clark WF , Rock GA , Buskard N , et al . Therapeutic plasma exchange: an update from the Canadian apheresis group. Ann Intern Med 1999.","DOI":"10.7326\/0003-4819-131-6-199909210-00011"},{"key":"2025090409492862000_20.2.92.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826aac4e"},{"key":"2025090409492862000_20.2.92.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304"},{"key":"2025090409492862000_20.2.92.18","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2025090409492862000_20.2.92.19","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"2025090409492862000_20.2.92.20","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21050"},{"key":"2025090409492862000_20.2.92.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70253-2"},{"key":"2025090409492862000_20.2.92.22","unstructured":"Linz C . Crookston and Vrielink. In: Principles of Apheresis Technology. 5th edn, 2014."},{"key":"2025090409492862000_20.2.92.23","doi-asserted-by":"crossref","unstructured":"Bonnan M , Valentino R , Debeugny S , et al . Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018.","DOI":"10.1136\/jnnp-2017-316286"},{"key":"2025090409492862000_20.2.92.24","doi-asserted-by":"crossref","unstructured":"Ebadi H , Barth D , Bril V . Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle and Nerve 2013.","DOI":"10.1002\/mus.23626"},{"key":"2025090409492862000_20.2.92.25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/tme.12205","article-title":"Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for standards in haematology","volume":"25","author":"Howell","year":"2015","journal-title":"Transfus Med"},{"key":"2025090409492862000_20.2.92.26","doi-asserted-by":"crossref","unstructured":"van Doorn PA , Ruts L , Jacobs BC . Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome. Lancet Neurol 2008.","DOI":"10.1016\/S1474-4422(08)70215-1"},{"key":"2025090409492862000_20.2.92.27","doi-asserted-by":"crossref","unstructured":"Chevret S , Hughes RAC , Annane D , et al . Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2017;37.doi:10.1002\/14651858.CD001798.pub3","DOI":"10.1002\/14651858.CD001798.pub3"},{"key":"2025090409492862000_20.2.92.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b1f6"},{"key":"2025090409492862000_20.2.92.29","doi-asserted-by":"crossref","unstructured":"Schwartz J , Padmanabhan A , Aqui N , et al . Guidelines on the use of therapeutic apheresis in clinical Practice\u2014Evidence-Based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher 2016.","DOI":"10.1002\/jca.21470"},{"key":"2025090409492862000_20.2.92.30","doi-asserted-by":"crossref","unstructured":"Vallat JM , Sommer C , Magy L . Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010.","DOI":"10.1016\/S1474-4422(10)70041-7"},{"key":"2025090409492862000_20.2.92.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602203140801"},{"key":"2025090409492862000_20.2.92.32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.4.1055"},{"key":"2025090409492862000_20.2.92.33","doi-asserted-by":"crossref","unstructured":"Mehndiratta MM , Hughes RAC , Pritchard J , et al . Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2015;314.doi:10.1002\/14651858.CD003906.pub4","DOI":"10.1002\/14651858.CD003906.pub4"},{"key":"2025090409492862000_20.2.92.34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(2000)15:1\/2<74::AID-JCA6>3.0.CO;2-O"},{"key":"2025090409492862000_20.2.92.35","doi-asserted-by":"crossref","unstructured":"Qureshi AI , Suri MFK . Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 2000.","DOI":"10.1046\/j.1526-0968.2000.004004280.x"},{"key":"2025090409492862000_20.2.92.36","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.10.1080"},{"key":"2025090409492862000_20.2.92.37","doi-asserted-by":"crossref","unstructured":"Nagayasu T , Yamayoshi T , Matsumoto K , et al . Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Japanese J Thorac Cardiovasc Surg 2005.","DOI":"10.1007\/s11748-005-1001-y"},{"key":"2025090409492862000_20.2.92.38","doi-asserted-by":"crossref","unstructured":"Gajdos P , Chevret S , Toyka KV , et al . Plasma exchange for generalised myasthenia gravis. Cochrane Database Syst Rev 2002;12.doi:10.1002\/14651858.CD002275","DOI":"10.1002\/14651858.CD002275"},{"key":"2025090409492862000_20.2.92.39","doi-asserted-by":"crossref","unstructured":"Rison RA , Beydoun SR . Paraproteinemic neuropathy: a practical review. BMC Neurol 2016;16.doi:10.1186\/s12883-016-0532-4","DOI":"10.1186\/s12883-016-0532-4"},{"key":"2025090409492862000_20.2.92.40","doi-asserted-by":"crossref","unstructured":"Dyck PJ , Low PA , Windebank AJ , et al . Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991.","DOI":"10.1056\/NEJM199111213252105"},{"key":"2025090409492862000_20.2.92.41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ncl.2012.09.005","article-title":"Stiff person syndrome","volume":"31","author":"Ciccotto","year":"2013","journal-title":"Neurol Clin"},{"key":"2025090409492862000_20.2.92.42","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/trf.12573","article-title":"Efficacy of therapeutic plasma exchange for treatment of stiff-person syndrome","volume":"54","author":"Pagano","year":"2014","journal-title":"Transfusion"},{"key":"2025090409492862000_20.2.92.43","doi-asserted-by":"crossref","unstructured":"Albahra S , Yates SG , Joseph D , et al . Role of plasma exchange in stiff person syndrome. Transfus Apher Sci 2019.","DOI":"10.1016\/j.transci.2019.03.015"},{"key":"2025090409492862000_20.2.92.44","unstructured":"Gibberd FB , Billimoria JD , Goldman JM , et al . Heredopathia atactica polyneuritiformis: Refsum\u2019s disease. Acta Neurol Scand 1985."},{"key":"2025090409492862000_20.2.92.45","doi-asserted-by":"crossref","unstructured":"Gibberd FB . Plasma exchange for Refsum\u2019s disease. Transfus Sci 1993.","DOI":"10.1016\/0955-3886(93)90049-Z"},{"key":"2025090409492862000_20.2.92.46","doi-asserted-by":"crossref","unstructured":"Harari D , Gibberd FB , Dick JPR , et al . Plasma exchange in the treatment of Refsum\u2019s disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry 1991.","DOI":"10.1136\/jnnp.54.7.614"},{"key":"2025090409492862000_20.2.92.47","doi-asserted-by":"crossref","unstructured":"Zolotov D , Wagner S , Kalb K , et al . Long-term strategies for the treatment of Refsum\u2019s disease using therapeutic apheresis. J Clin Apher 2012.","DOI":"10.1002\/jca.21200"},{"key":"2025090409492862000_20.2.92.48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.10.1257"},{"key":"2025090409492862000_20.2.92.49","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511430704"},{"key":"2025090409492862000_20.2.92.50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.1.143"},{"key":"2025090409492862000_20.2.92.51","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.39.9.1143","article-title":"Double-Blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"39","author":"Weiner","year":"1989","journal-title":"Neurology"},{"key":"2025090409492862000_20.2.92.52","doi-asserted-by":"crossref","unstructured":"Bigi S , Banwell B , Yeh EA . Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination. J Child Neurol 2015.","DOI":"10.1177\/0883073814545883"},{"key":"2025090409492862000_20.2.92.53","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q"},{"key":"2025090409492862000_20.2.92.54","doi-asserted-by":"crossref","unstructured":"Argyriou AA , Makris N . Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008.","DOI":"10.1111\/j.1600-0404.2008.01002.x"},{"key":"2025090409492862000_20.2.92.55","doi-asserted-by":"crossref","unstructured":"Bonnan M , Cabre P . Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012.","DOI":"10.1155\/2012\/787630"},{"key":"2025090409492862000_20.2.92.56","unstructured":"Kleiter I , Gahlen A , Borisow N , et al . Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016."},{"key":"2025090409492862000_20.2.92.57","doi-asserted-by":"crossref","unstructured":"Rudick RA , Cohen JA , Weinstock-Guttman B , et al . Management of multiple sclerosis. N Engl J Med 1997.","DOI":"10.1056\/NEJM199711273372207"},{"key":"2025090409492862000_20.2.92.58","doi-asserted-by":"crossref","unstructured":"Weinstein R . Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. J Clin Apher 2008.","DOI":"10.1002\/jca.20178"},{"key":"2025090409492862000_20.2.92.59","doi-asserted-by":"crossref","unstructured":"Klingel R , Heibges A , Fassbender C . Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies - Perspectives for immunoadsorption. Atheroscler Suppl 2013.","DOI":"10.1016\/j.atherosclerosissup.2012.10.024"},{"key":"2025090409492862000_20.2.92.60","doi-asserted-by":"crossref","unstructured":"Keegan M , K\u00f6nig F , McClelland R , et al . Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005.","DOI":"10.1016\/S0140-6736(05)67102-4"},{"key":"2025090409492862000_20.2.92.61","doi-asserted-by":"crossref","unstructured":"Dubey D , Pittock SJ , Kelly CR , et al . Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018.","DOI":"10.1002\/ana.25230"},{"key":"2025090409492862000_20.2.92.62","doi-asserted-by":"crossref","unstructured":"Buckley C , Oger J , Clover L , et al . Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001.","DOI":"10.1002\/ana.1097"},{"key":"2025090409492862000_20.2.92.63","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh077"},{"key":"2025090409492862000_20.2.92.64","doi-asserted-by":"crossref","unstructured":"Wong SH , Saunders MD , Larner AJ , et al . An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010.","DOI":"10.1136\/jnnp.2009.178293"},{"key":"2025090409492862000_20.2.92.65","doi-asserted-by":"crossref","unstructured":"Suppiej A , Nosadini M , Zuliani L , et al . Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev 2016.","DOI":"10.1016\/j.braindev.2016.01.009"},{"key":"2025090409492862000_20.2.92.66","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/cei.12185","article-title":"Paraneoplastic neurological syndromes","volume":"175","author":"Leypoldt","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025090409492862000_20.2.92.67","doi-asserted-by":"crossref","unstructured":"Rosenfeld MR , Dalmau J . Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Curr Neurol Neurosci Rep 2006.","DOI":"10.1007\/s11910-996-0012-0"},{"key":"2025090409492862000_20.2.92.68","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2318::AID-CNCR2820560930>3.0.CO;2-9"},{"key":"2025090409492862000_20.2.92.69","unstructured":"Ben DY , Warner E , Levitan M , et al . Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: a case report. Cancer 1996."},{"key":"2025090409492862000_20.2.92.70","doi-asserted-by":"crossref","unstructured":"Taniguchi Y , Tanji C , Kawai T , et al . A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody. Ther Apher Dial 2006.","DOI":"10.1111\/j.1744-9987.2006.00348.x"},{"key":"2025090409492862000_20.2.92.71","doi-asserted-by":"crossref","unstructured":"Rickman OB , Parisi JE , Yu Z , et al . Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 2000.","DOI":"10.4065\/75.12.1321"},{"key":"2025090409492862000_20.2.92.72","doi-asserted-by":"crossref","unstructured":"Armstrong MB , Robertson PL , Delayed CVP . Recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol 2005.","DOI":"10.1016\/j.pediatrneurol.2005.05.018"},{"key":"2025090409492862000_20.2.92.73","doi-asserted-by":"crossref","unstructured":"Weissman DE , Gottschall JL . Complete remission of paraneoplastic sensorimotor neuropathy: a case associated with small\u2010cell lung cancer responsive to chemotherapy, plasma exchange, and radiotherapy. J Clin Apher 1989.","DOI":"10.1002\/jca.2920050104"},{"key":"2025090409492862000_20.2.92.74","doi-asserted-by":"crossref","unstructured":"Swedo SE , Leonard HL , Garvey M , et al . Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998.","DOI":"10.1176\/ajp.155.2.264"},{"key":"2025090409492862000_20.2.92.75","doi-asserted-by":"crossref","unstructured":"Perlmutter SJ , Leitman SF , Garvey MA , et al . Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999.","DOI":"10.1016\/S0140-6736(98)12297-3"},{"key":"2025090409492862000_20.2.92.76","doi-asserted-by":"crossref","unstructured":"Latimer ME , L\u2019Etoile N , Seidlitz J , et al . Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol 2015.","DOI":"10.1089\/cap.2014.0080"},{"key":"2025090409492862000_20.2.92.77","doi-asserted-by":"crossref","unstructured":"Cardoso F , Seppi K , Mair KJ , et al . Seminar on choreas. Lancet Neurol 2006.","DOI":"10.1016\/S1474-4422(06)70494-X"},{"key":"2025090409492862000_20.2.92.78","doi-asserted-by":"crossref","unstructured":"Garvey MA , Snider LA , Leitman SF , et al . Treatment of sydenham\u2019s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005.","DOI":"10.1177\/08830738050200050601"},{"key":"2025090409492862000_20.2.92.79","doi-asserted-by":"crossref","unstructured":"Miranda M , Walker RH , Saez D , et al . Severe Sydenham\u2019s chorea (chorea paralytica) successfully treated with plasmapheresis. J Clin Mov Disord 2015;2.doi:10.1186\/s40734-014-0012-1","DOI":"10.1186\/s40734-014-0012-1"},{"key":"2025090409492862000_20.2.92.80","unstructured":"Jennings R , Osman C , Hill K , et al . Outpatient plasma exchange: the Wessex experience. J Neurol Neurosurg Psychiatry 2019."},{"key":"2025090409492862000_20.2.92.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2019-002336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T16:49:49Z","timestamp":1757004589000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2019-002336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,3,17]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/practneurol-2019-002336"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2019-002336","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]}}}